Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Is Spire Healthcare a Defensive Stock Under Pressure?

Spire Healthcare Group PLC(LSE:SPI) has come under pressure in today’s trading session, reflecting a combination of valuation sensitivity, cost concerns, and broader market sentiment. As one of the UK’s leading independent healthcare providers, LSE:SPI operates in a relatively defensive sector, but its share price …

Ankur Sharma | 24 April 2026

What’s Behind the Sharp Rise in Inspiration Healthcare Stock?

Introduction: Why Did Inspiration Healthcare Stock Move Today?

Ankur Sharma | 24 April 2026

How Strong Is Demand for Asthma Diagnostics Like NIOX?

Introduction: Why Did NIOX Stock Move Today?

Ankur Sharma | 24 April 2026

Is Convatec a Defensive Stock Under Pressure?

Convatec Group Plc(LSE:CTEC) has declined in today’s trading session, reflecting mixed sentiment in the healthcare and medical products sector. As a global provider of medical products and technologies focused on chronic conditions, LSE:CTEC is generally considered a defensive stock. However, the recent weakness appears …

Ankur Sharma | 24 April 2026

Why are pharma stocks like Hikma rising in today’s volatile market?

Why Is LSE:HIL Stock Rising Today and What Are the Key Drivers Behind the Surge?

Ankur Sharma | 23 April 2026

What Risks Should Investors Watch in Ondine Biomedical?

Ondine Biomedical Inc. is a Canada-based life sciences company focused on developing photodisinfection-based therapies aimed at preventing and treating infections. Its core technology uses light-activated antimicrobial agents to eliminate a broad spectrum of pathogens, including bacteria, viruses, and fungi. The company primarily targets hospital-acquired …

Ishan Mudgal | 23 April 2026

How Strong Is HemoGenyx’s CAR-T and Bispecific Pipeline?

The company's pipeline is built around two complementary programmes. The first is its CDX bispecific antibody, designed to redirect a patient's own immune cells against AML blasts by engaging a tumour-associated antigen alongside a T-cell activating arm. The second is HG-CT-1, an autologous CAR-T …

Ishan Mudgal | 23 April 2026

How Strong Is HemoGenyx’s CAR-T and Bispecific Pipeline?

The company's pipeline is built around two complementary programmes. The first is its CDX bispecific antibody, designed to redirect a patient's own immune cells against AML blasts by engaging a tumour-associated antigen alongside a T-cell activating arm. The second is HG-CT-1, an autologous CAR-T …

Ankur Sharma | 23 April 2026

Are Diagnostics Stocks Like ABDX Gaining Investor Attention Again?

Introduction: Why Did Abingdon Health Stock Move Today?

Ankur Sharma | 23 April 2026

We use cookies to help us improve, promote, and protect our services. By continuing to use this site, we assume you consent to our Cookies Policy. For more information, read our Privacy Policy and Terms and Conditions